Acrivon Therapeutics News

Express News | BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $25 Price Target

BenzingaMay 15 08:55 ET

Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)

TipRanksMay 14 23:20 ET

Acrivon Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Acrivon Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 14 13:28 ET

Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)

TipRanksMay 14 12:10 ET

Express News | Acrivon Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $22 From $20

ReutersMay 14 11:59 ET

Acrivon Therapeutics 1Q Loss/Shr 73c >ACRV

Acrivon Therapeutics 1Q Loss/Shr 73c >ACRV

Dow JonesMay 14 08:01 ET

Express News | Acrivon Therapeutics, Inc Q1 Net Income USD -16.486 Million Vs. Ibes Estimate USD -20.5 Million

ReutersMay 14 08:00 ET

Express News | Acrivon Therapeutics, Inc Q1 Operating Expenses USD 17.668 Million

ReutersMay 14 08:00 ET

Express News | Acrivon Therapeutics, Inc Q1 Basic EPS USD -0.73

ReutersMay 14 08:00 ET

Press Release: Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeu

Dow JonesMay 14 08:00 ET

Acrivon Therapeutics | 10-Q: Quarterly report

SEC announcementMay 14 07:34 ET · Announcements

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision on

Acrivon TherapeuticsMay 14 00:00 ET

Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral

Acrivon Therapeutics (ACRV) Price: 8.28, Change: -0.18, Percent Change: -2.13

MT NewswiresApr 29 07:08 ET

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)

TipRanksApr 27 08:10 ET

Acrivon Therapeutics Is Maintained at Outperform by BMO Capital

Acrivon Therapeutics Is Maintained at Outperform by BMO Capital

Dow JonesApr 26 14:12 ET

Express News | BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25

BenzingaApr 26 14:01 ET

Buy Rating on Acrivon Therapeutics With Increased Target Price Amid Promising ACR-368 Trial Data

TipRanksApr 26 07:20 ET

Express News | Acrivon Therapeutics Inc : BMO Raises Target Price to $25 From $18

ReutersApr 26 07:01 ET

Acrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potential

TipRanksApr 25 12:46 ET

Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler

Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler

Dow JonesApr 25 09:04 ET